舒绍坤，北京大学国际癌症研究院、北京大学肿瘤医院、北京大学-云南白药国际医学研究中心研究员、博士生导师。主要聚焦肿瘤表观遗传学靶点和靶向药物研究，通过结合多组学手段和高通量功能基因组筛选平台，鉴定肿瘤新靶点，进行靶向药物临床前试验，研究其作用机理，推动创新药的临床实验; 利用高通量多组学技术研究肿瘤耐药机理，找到克服肿瘤耐药的联合用药方案，推动临床试验。近年来，研究论文以第一作者发表在Nature，Molecular Cell等杂志，研究工作曾被同期Nature和Molecular Cell杂志以News & Review长文报道，启动和参与两项二期临床实验。加入BBA Reviews on Cancer Editorial Board，入选“青年长江”和“高层次留学回国人才”资助，主持科技部重点研发计划子课题和国家自然科学基金面上项目。

代表性学术成果

1．Shaokun Shu; Charles Y. Lin; Housheng Hansen He; Robert M. Witwicki……James E. Bradner; Kornelia Polyak; Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer, Nature, 2016, 529: 413-417.

2．Shaokun Shu; Hua-Jun Wu; Jennifer Y. Ge……James Bradner; Franziska Michor; Kornelia Polyak; Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triplenegative breast cancer, Molecular Cell, 2020, 78: 1-18.

3．Jennifer Y. Ge; Shaokun Shu……Franziska Michor; Kornelia Polyak; Acquired resistance to combined BET and CDK4/6 inhibition throughadaptation to tetraploidy, Nature Communication, 2020, 11.

4．Shu S, Polyak K. BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harbor Symposia on Quantitative Biology. 2016;81:123-129.